While a pan-cancer epitope vaccine targeting various PIK3CA gene mutations has not been developed yet, an in vitro study focused on the H1047R point mutation, using PBMCs from healthy individuals, induced T-cell responses [14]. Here, PIK3CA is linked to cancer.